Zhejiang Jolly PharmaceuticalLTD Future Growth
Future criteria checks 5/6
Zhejiang Jolly PharmaceuticalLTD is forecast to grow earnings and revenue by 23.3% and 22.5% per annum respectively. EPS is expected to grow by 23% per annum. Return on equity is forecast to be 23.3% in 3 years.
Key information
23.3%
Earnings growth rate
23.0%
EPS growth rate
Pharmaceuticals earnings growth | 18.8% |
Revenue growth rate | 22.5% |
Future return on equity | 23.3% |
Analyst coverage | Low |
Last updated | 21 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 4,085 | 861 | 500 | 848 | 2 |
12/31/2025 | 3,280 | 686 | 384 | 693 | 2 |
12/31/2024 | 2,605 | 548 | 257 | 605 | 2 |
9/30/2024 | 2,522 | 518 | 116 | 279 | N/A |
6/30/2024 | 2,359 | 481 | 245 | 381 | N/A |
3/31/2024 | 2,120 | 428 | 145 | 294 | N/A |
12/31/2023 | 1,942 | 383 | 157 | 288 | N/A |
9/30/2023 | 1,926 | 356 | 162 | 349 | N/A |
6/30/2023 | 1,922 | 336 | 137 | 310 | N/A |
3/31/2023 | 1,861 | 302 | 91 | 245 | N/A |
1/1/2023 | 1,805 | 273 | 141 | 319 | N/A |
9/30/2022 | 1,723 | 252 | 58 | 260 | N/A |
6/30/2022 | 1,655 | 228 | 75 | 290 | N/A |
3/31/2022 | 1,557 | 204 | 74 | 290 | N/A |
1/1/2022 | 1,457 | 179 | 104 | 252 | N/A |
9/30/2021 | 1,400 | 158 | 234 | 319 | N/A |
6/30/2021 | 1,322 | 145 | 269 | 336 | N/A |
3/31/2021 | 1,238 | 122 | 267 | 327 | N/A |
12/31/2020 | 1,091 | 89 | 221 | 280 | N/A |
9/30/2020 | 1,024 | 49 | 180 | 222 | N/A |
6/30/2020 | 949 | 29 | 82 | 118 | N/A |
3/31/2020 | 901 | 26 | 112 | 148 | N/A |
12/31/2019 | 911 | 26 | 88 | 129 | N/A |
9/30/2019 | 859 | 34 | 109 | 160 | N/A |
6/30/2019 | 767 | 14 | 39 | 131 | N/A |
3/31/2019 | 764 | 23 | -5 | 104 | N/A |
12/31/2018 | 730 | 21 | -76 | 78 | N/A |
9/30/2018 | 609 | 20 | -125 | 36 | N/A |
6/30/2018 | 629 | 31 | N/A | 102 | N/A |
3/31/2018 | 647 | 43 | N/A | 20 | N/A |
12/31/2017 | 679 | 45 | N/A | 8 | N/A |
9/30/2017 | 804 | 49 | N/A | 114 | N/A |
6/30/2017 | 814 | 63 | N/A | 21 | N/A |
3/31/2017 | 830 | 59 | N/A | 54 | N/A |
12/31/2016 | 840 | 72 | N/A | 58 | N/A |
9/30/2016 | 819 | 86 | N/A | 22 | N/A |
6/30/2016 | 810 | 87 | N/A | 78 | N/A |
3/31/2016 | 720 | 85 | N/A | 112 | N/A |
12/31/2015 | 671 | 85 | N/A | 97 | N/A |
9/30/2015 | 657 | 103 | N/A | 16 | N/A |
6/30/2015 | 620 | 111 | N/A | -18 | N/A |
3/31/2015 | 572 | 107 | N/A | -39 | N/A |
12/31/2014 | 515 | 103 | N/A | 14 | N/A |
9/30/2014 | 457 | 94 | N/A | 13 | N/A |
6/30/2014 | 440 | 90 | N/A | 35 | N/A |
3/31/2014 | 431 | 85 | N/A | 42 | N/A |
12/31/2013 | 419 | 81 | N/A | 30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300181's forecast earnings growth (23.3% per year) is above the savings rate (2.8%).
Earnings vs Market: 300181's earnings (23.3% per year) are forecast to grow slower than the CN market (26.2% per year).
High Growth Earnings: 300181's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300181's revenue (22.5% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 300181's revenue (22.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300181's Return on Equity is forecast to be high in 3 years time (23.3%)